Karuna Therapeutics Inc

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Karuna Therapeutics reports positive trial results and strong financial outlook

Karuna Therapeutics is making significant progress in its key programs, with positive trial results and a focus on expanding its pipeline. Despite challenges in trial timelines and increased expenses, the company's strong financial position and strategic priorities position it well for future growth.

Karuna Therapeutics reports robust Q2 performance and eyes new indications

Karuna Therapeutics reported strong financials, progress on NDA submission, and ongoing Phase III programs.
The company's focus on cognitive benefits, broader efficacy, and potential new indications showcases strategic growth initiatives.
Challenges include competitive dynamics in Alzheimer's trials and uncertainties in the applicability of KarXT in certain patient populations.
Opportunities lie in exploring new indications, demonstrating cognitive benefits, and enhancing efficacy in mood and anxiety disorders.

Karuna Therapeutics excels in Q3, eyes global expansion for KarXT

Karuna Therapeutics demonstrated strong performance in Q3 with a focus on KarXT Phase III programs and NDA submission, supported by a healthy financial position.
Strategic strengths lie in maximizing KarXT value, positive payer interactions, and broad-based commercial strategies, while challenges include managing expenses and operational considerations.
Opportunities for growth include expanding the TRPC4/5 program, leveraging favorable mental health trends, and pursuing international market partnerships for KarXT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Digital Turbine

Bloom Energy

eXp World Holdings Inc

Inovio Pharmaceuticals

Overstock.com

Vivint Solar

It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.

7 Risky Stocks to Buy Now for Growth and Exciting Returns

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Laurie Olson to its Board of Directors effective August 12, 2020.

Karuna Therapeutics Appoints Laurie Olson to Board of Directors

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced financial results for the second quarter of 2020 and provided a general business update.

 Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced results from KAR-020, its Phase 1b trial evaluating the analgesic effects of KarXT on experimentally induced pain in healthy volunteers.

Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers

BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc.

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced next steps in the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia following the completion of a successful End-of-Phase 2 meeting with the U.

Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against Karuna Therapeutics (KRTX) Stock

Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)

Livongo Health Inc

PennyMac Financial Services

Sprouts Farmers Markets

Strayer Education

Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.

5 Top Mid-Cap Stocks Surging Despite Coronavirus Concerns

As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).

Karuna Therapeutics, Inc. (KRTX) Shares March Higher, Can It Continue?

Beyond Meat

Lyft

Uber

COVID-19 and initial public offerings don’t go well together.

The Coronavirus Pandemic Will Delay 2020 IPOs

The volatile biotech has been up and down since its massive gain back in November.

Why Did Karuna Therapeutics Pop 26% in January?

The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.

Why Karuna Therapeutics Shares Sank Today

Cortexyme Inc

IGM Biosciences Inc

Inmode Ltd

Nextcure

Palomar

Shockwave Medical

Turning Point Therapeutics

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who didn’t buy into the hype of more familiar names like Uber or Lyft.

Non-Household Names Topped the List of IPO Winners in 2019

Applied Therapeutics Inc

Aprea Therapeutics

BioNTech SE

Glaukos

Rapt Therapeutics Inc

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

These Were the 10 Best IPOs of 2019

Silk Road Medical Inc

Zoom Video

This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

5 Best Performing IPOs of 2019

Chewy

An index that tracks initial public offerings has outperformed the S&P 500 in what could be a historic year for stocks.

IPOs overall beat the market this year despite some 'mega busts'

Is the stock a buy now that the price has dropped?

Karuna Therapeutics' Crash Reminds Investors How Dangerous Biotech Stocks Can Be

Axsome Therapeutics

Kodiak Sciences Inc

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?

Can These Soaring Biotech Stocks Fly Higher?

In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.

The Price of Karuna Therapeutics Stock Is Too Tough to Swallow

ACADIA Pharma

Neurocrine Biosciences

Minerva Neurosciences

4 Biotech Neurology Stocks, As Biotechs March On

Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock.

What to Do with Karuna Stock After It Soared and Then Plunged

As of late, it has definitely been a great time to be an investor Karuna Therapeutics

Karuna Therapeutics Shares March Higher, Can It Continue?

Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia Study

Should You Sell or Hold a Stock after a 6X Gain in Two Days?

News for Karuna Therapeutics Inc Stock (KRTX)